Skip to main content

Table 1 Terms used for the literature review search using the PICO Format

From: Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

Population with or without treatment Patients with rheumatoid arthritis OR juvenile idiopathic arthritis OR systemic lupus erythematosus OR systemic sclerosis OR psoriatic arthritis OR spondyloarthritis OR Sjögren’s syndrome OR vasculitis OR inflammatory myopathy OR dermatomyositis OR psoriasis OR Crohn’s disease OR ulcerative colitis
Intervention yellow fever vaccine
Comparison Placebo OR no intervention
Outcomes immunization, safety, severe adverse events, viscerotropic disease associated with yellow fever vaccine, immunogenicity, response, effectiveness, efficacy, seroconversion, disease activity: DAS28, ACR 30/50/70. BASDAI, SLEDAI, HAQ / CHAQ, VASDAI, CMAS, MMT
  1. Terms used for the search related to treatment: abatacept, acitretin, adalimumab, anti-CD20, anti-IL-1, anti-IL-6, anti-IL17, anti-IL23, anti-JAK, anti-TNF, azathioprine, belimumab, canakinumab, certolizumab, cyclophosphamide, CTLA4 IgG, etanercept, golimumab, hydroxychloroquine, infliximab, leflunomide, methotrexate, methylprednisolone, mycophenolate mofetil, prednisolone, prednisone, rituximab, secukinumab, sulfasalazine, tacrolimus, tocilizumab, tofacitinib, ustequikinumab